Emyria Ltd · ASX:EMD
Emyria — Share Café June 2021 "Hidden Gems": medicinal cannabis/hemp Webinar
25 slides from Emyria's conference presentation, Jun 18, 2021
Slide 1: Share Café June 2021 Hidden Gems: medicinal cannabis/hemp Webinar
For personal use only Share Café June 2021 "Hidden Gems”: medicinal cannabis/ hemp Webinar Michael Winlo ASX:EMD
Slide 2: Disclaimer and notices
Disclaimer and notices This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any ju
Slide 3: Emyria develops registered treatments for under-served populations
For personal use only Emyria develops registered treatments for large, under-served populations powered by proprietary clinical evidence Capital Structure 12month price chart Key Metrics Value Ordinary shares 225.5 Last close (04 March 2021) A$0.18 Market Capitalisation (Date) A$45.7m Cash (31 March
Slide 4: Emyria provides care + data to support drug registration
Emyria provides care + data to support drug registration For personal use only Emyria’s current drug Emyria Care Emyria Data registration programs CBD medicine targeting mental health EMD-003 CBD +/- THC for • 7 sites around Australia • Millions of data points irritable bowel • 4,000 patients and gr
Slide 5: Emyria data is the brain of our company
Emyria data is the brain of our company Emyria Data For personal use only Millions of unique data points An intelligent model for care & drug design 5
Slide 6: Emyria provides care for more than unmet needs
Emyria provides care for more than 40 unmet needs… For personal use only Mental Health • Insomnia • PTSD • Anxiety disorders 12% Chronic Non-Cancer Pain • Neuropathic Cancer symptoms • Inflammatory • Pain 66% • Mixed 9% • CINV • Migraine • Anorexia 6% Neurological disorders • Dementia 8% • Multiple
Slide 7: Each unmet need is an opportunity
…each unmet need is an opportunity For personal use only Disease severity Less Greater (Clinical management intensity) EMD-003 EMDMA-001 Cannabinoid medicine (over-the- Psychedelic-assisted counter) for psychological distress therapy for PTSD S3 S4 S8 S9 TGA Schedules
Slide 8: Emyria pipeline + global registration plans
Emyria pipeline + global registration plans For personal use only Program Target Develop Gather real- Analysis Develop Commence Submit for indication care model world & IP product pivotal registration evidence capture trials Aus FDA/EMA Psychological EMD-003 Neuroscience distress EMDMA-001 PTSD MDMA
Slide 9: Registering treatments creates value
For personal use only Registering treatments creates value DRAFT 9
Slide 10: Medicinal cannabis in Australia
Medicinal cannabis in Australia For personal use only 150+ medicinal cannabis Medicinal cannabis products are products available in “unregistered” meaning, they are Australia only available to patients via Special Access Schemes, Authorised Prescriber programs or clinical trials* * only 1 product is
Slide 11: Medicinal cannabis vs registered prescriptions
~ 5,833,000 / month Medicinal cannabis vs registered prescriptions For personal use only (via select drug groupings in Australia + UK over 12 months) Registered treatments (i.e. routine prescription) 70,000,000 Medicinal cannabis ~ 2,416,000 / month (via Special Access Scheme) ~8,500 / month 29,112,
Slide 12: Recent deals: Jazz acquires GW Pharma
Recent deals | Jazz acquires GW Pharma ($7.2B USD) For personal use only Emyria recently appointed Dr Karen Smith, Ex-Chief Medical Officer and Global Head of Research & Development at Jazz Pharmaceuticals to Chair Emyria’s Strategic Advisory (See ASX Announcement 22 February 2021) 12
Slide 13: Emyria's impact so far
For personal use only Emyria’s impact so far… DRAFT 13
Slide 14: Case Study - Bob
Case Study - Bob For personal use only • Vietnam Veteran | injured by fall in 1969 | multiple fractures • Chronic back pain | peripheral neuropathy from Agent Orange | PTSD • At initial visit: oxycontin | buprenorphine | pregabalin | gabapentin | PEA duloxetine – with little relief and side effects.
Slide 15: Emyria's care model works + our data is validated
Emyria’s care model works… + our data is validated Average opioid scores by oMEDD category (Pre vs Post Emyria) For personal use only 240 Prior care 216 Patients with 6+ months of cannabinoid usage 192 Significant 168 High. >90mg/day 30+% reduction 144 oMEDD score The oral morphine equivalent daily
Slide 16: EMD-003 Snapshot
For personal use only EMD-003 Snapshot DRAFT 16
Slide 17: EMD-003: Unique success factors in place
EMD-003: Unique success factors in place Strategic partnership accelerates path to S3 registration For personal use only Real-world IP on Streamlined Protocols Regulatory Experienced data on “method of access to developed strategy drug emyria safety & use” patients + development efficacy at clinical
Slide 18: EMD-003: Milestones in year ahead
EMD-003: Milestones in year ahead Value drivers next 12 months For personal use only Commence Complete Prepare product Obtain Finalise Commence pivotal trial and dossier and submit Schedule 3 commercialisation international registration commence to TGA for registration agreements + registration clin
Slide 19: Emyria pipeline + global registration plans
Emyria pipeline + global registration plans For personal use only Program Target Develop Gather real- Analysis Develop Commence Submit for indication care model world & IP product pivotal registration evidence capture trials Aus FDA/EMA Psychological EMD-003 Neuroscience distress EMDMA-001 PTSD MDMA
Slide 20: Thank-you and questions
For personal use only Thank-you and questions DRAFT 20
Slide 21: Contact Information
For personal use only Contact Information Michael Winlo: mwinlo@emyria.com Investors: investors@emyria.com Media: media@emyria.com General: info@emyria.com ASX:EMD
Slide 22: Appendix
For personal use only Appendix DRAFT 22
Slide 23: Board with deep clinical and commercial expertise
Board with deep clinical and commercial expertise Key Person Role For personal use only Dr Stewart Washer Cynata (ASX:CYP) – stem cells Orthocell (ASX:OCC) – regenerative medicine Chairman & Founder Botanix (ASX:BOT) – CBD (synthetic) Dr Michael Winlo Medical doctor Director at Linear Clinical Manag
Slide 24: Recently appointed Key Advisors
Recently appointed Key Advisors For personal use only Key Person Role • Experienced pharmaceutical expert • Multiple Directorships with innovative pharmaceutical companies • Ex-Chief Medical Officer and Global Head of R&D Dr Karen Smith M.D., Ph.D., M.B.A., L.L.M at Jazz Pharmaceuticals • Overseen m
Slide 25: Since listing, we have
Since listing, we have… For personal use only • Over 4,000 patients with unmet needs • Launched 3 drug registration programs: • 7 clinic locations Emerald Clinics • EMD-003 (schedule 3 medicine for psychological distress) • Specialist advisors & GCP-trained GPs • EMD-004 (cannabinoid for IBS) • Over
Emyria — Share Café June 2021 "Hidden Gems": medicinal cannabis/hemp Webinar on 6ix